eligibility_summary
Adults >=18 with invasive, HER2+ breast cancer (cT2-cT4 or any cT with cN1-cN3), ECOG 0-1, LVEF >=50%, adequate labs, known ER/PR, tissue/blood available, negative pregnancy test/contraception, consent/compliance. Exclude distant mets, prior invasive BC, recent other malignancy, major cardiac/QT issues, ILD/serious lung disease, HIV/HBV/HCV, GI malabsorption, QT-risk/CYP3A meds, recent live vaccine, pregnancy, recent/axillary surgery, effusions needing drainage, other trials/allergy.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT05900206 (ARIADNE) compares neoadjuvant trastuzumab deruxtecan (T-DXd) vs standard TCHP/PCHP, then tailors cycles 4–6 by PAM50 subtype. Drugs/MOAs (type): T-DXd—HER2-targeted antibody–drug conjugate delivering a topoisomerase I inhibitor (ADC). Trastuzumab—anti-HER2 monoclonal antibody (mAb, signaling blockade, ADCC). Pertuzumab—anti-HER2 mAb blocking HER2/HER3 dimerization. Docetaxel/Paclitaxel—taxane chemotherapies (microtubule stabilizers). Carboplatin—platinum chemotherapy (DNA crosslinks). Ribociclib—CDK4/6 inhibitor (targeted, G1 arrest). Letrozole—aromatase inhibitor (endocrine, lowers estrogen). Epirubicin—anthracycline chemotherapy (Topo II inhibition, DNA damage). Cyclophosphamide—alkylating chemotherapy (DNA crosslinks). Targets: HER2-overexpressing tumor cells, HER2 signaling/dimerization, Topo I/II, microtubules, DNA crosslink/repair, ER pathway, CDK4/6–RB cell cycle, Fc-mediated ADCC via immune effector cells.